Neuronetics STIM Medical Device — Research And Development Expense
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Neuronetics in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Neuronetics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Neuronetics's medical device — research and development expense.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Neuronetics's medical device — research and development expense?
- Neuronetics (STIM) reported medical device — research and development expense of $1.31M in Q1 2026.
- How has Neuronetics's medical device — research and development expense changed year-over-year?
- Neuronetics's medical device — research and development expense decreased by 16.6% year-over-year, from $1.57M to $1.31M.
- What is the long-term trend for Neuronetics's medical device — research and development expense?
- Over 3 years (2022 to 2025), Neuronetics's medical device — research and development expense has grown at a 26.0% compound annual growth rate (CAGR), from $3.83M to $7.66M.
- What does medical device — research and development expense mean?
- This metric tracks the investment in activities related to the design, development, and improvement of medical device technologies. It is a critical indicator of the company's commitment to innovation and its long-term strategy to maintain a competitive product pipeline.